Q1 2014

Source filing unavailable

Q1 2014 · —

Revenue—

Net Income

-$2.83M

N/M vs Q1 2013

EPS Diluted

-$18.09

N/M vs Q1 2013

Operating Income-$1,933,000—

Operating Cash Flow-$1,562,000—

Same quarter

Metric	Q1 2014	Q1 2013
Net Income	-$2.83M	-$1.87M
EPS Diluted	-$18.09	-$14.64

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR